Description

The medtech CDMO market reached a value of $89B in 2024, driven by OEMs' increasing reliance on external development and manufacturing partners. This shift is creating both significant opportunities and new operational pressures for CDMOs and OEMs alike. While the market is expected to continue growing in 2025, the path forward is clouded by challenges such as supply chain disruptions, evolving regulatory landscapes, and geopolitical instability.  

How can stakeholders navigate these headwinds while maintaining momentum and strategic focus? Join the Alira Health team for a timely discussion on how medtech companies and CDMOs can balance risk and opportunity in a rapidly shifting environment.  

In this webinar you will:

• Consider how changes in the medical device industry, such as post-COVID normalization and destocking trends, trickle down to impact contract manufacturers today 
• Understand how CDMOs are creating competitive advantage through specialization and materials innovation, including advances in next-generation plastics  
• Identify the key players behind current M&A activity and which end markets are poised for further movement in 2025  

Speakers: 

• Sofia Puzzi, Principal, Alira Health 
• Eve Ogdon, Consultant, Alira Health

REGISTER NOW